Spurious medicines : DRAP cancels licence of drug manufacturer

Drap says the firm was found involved in manufacturing of spurious and unregistered medicines.

ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has cancelled the manufacturing licence of Everest Pharma, an Islamabad based firm, on Saturday.

According to Drap spokesperson, the licencing Board in its 258th meeting held earlier this week, cancelled the licence.

Drap said the firm was found involved in manufacturing of spurious and unregistered medicines. The spokesperson said that Everest Pharma did not get its drug manufacturing licence renewed after
March, 2014.



On the direction of Supreme Court a team of Drap officers along with FIA and NAB teams inspected the Everest Pharmaceuticals on March 6, 2018 and reported that firm is involved in manufacturing of unregistered, spurious and sex medicines.

Published in The Express Tribune, March 11^th, 2018.